Pharma Pioneer

Encouraging Phase 1 BEXMAB Study Results in High-Risk MDS and r/r AML Patients

19 May 2024
2 min read

Recent updates from the BEXMAB clinical trial indicate a positive trend in the treatment of high-risk (HR) myelodysplastic syndrome (MDS) patients who have not responded to hypomethylating agents (HMA). The trial, which has transitioned into Phase 2, has shown that a significant number of patients are still in remission after eight months, suggesting a promising survival benefit when compared to existing treatments. The initial Phase 1 cohort, consisting of HR HMA-failed MDS patients, demonstrated an 87.5% overall response rate, with responses ranging from complete remission to stable disease, despite one patient discontinuing due to a serious adverse event unrelated to the study drug.

The ongoing BEXMAB study, led by Principal Investigator Mika Kontro, MD, PhD, from the Helsinki University Hospital Comprehensive Cancer Center, is assessing the safety and efficacy of bexmarilimab in combination with the standard of care, azacitidine. Bexmarilimab, developed by Faron Pharmaceuticals Ltd., is an experimental immunotherapy that targets the Clever-1 receptor on macrophages, potentially enhancing the immune system's ability to combat cancer cells.

Faron Pharmaceuticals will host a virtual webinar on March 19 to delve into these findings. The company's CEO, Dr. Markku Jalkanen, expressed optimism about the potential of bexmarilimab to significantly improve patient outcomes, particularly for those suffering from aggressive forms of cancer. The data from the BEXMAB trial are expected to be instrumental in future discussions with regulatory authorities, such as the FDA, to advance the treatment's approval process.

The study's design focuses on the aggressive hematological malignancies of AML and MDS, with the primary goal of establishing the safety profile of bexmarilimab when combined with standard treatments. The drug's mechanism of action involves targeting Clever-1, which is highly expressed in both AML and MDS and is linked to therapy resistance and poor patient outcomes.

Faron Pharmaceuticals, a clinical-stage biopharmaceutical company, is dedicated to developing novel immunotherapies to address various cancers. Their lead asset, bexmarilimab, represents a new approach to cancer treatment by reprogramming myeloid cell function and activating anti-tumor immunity.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

ALG-801 Phase 1b MAD Clinical Trial Success Announced by AliveGen
Pharma Pioneer
2 min read
ALG-801 Phase 1b MAD Clinical Trial Success Announced by AliveGen
19 May 2024
In Thousand Oaks, California, AliveGen USA Inc. has announced the successful conclusion of its Phase 1b multiple-ascending dose (MAD) clinical trial for the novel drug ALG-801.
Read →
Rezatapopt Phase I Results in Advanced Ovarian Cancer Presented at 2024 SGO Meeting
Pharma Pioneer
3 min read
Rezatapopt Phase I Results in Advanced Ovarian Cancer Presented at 2024 SGO Meeting
19 May 2024
Rezatapopt is a groundbreaking targeted therapy for advanced solid tumors with the TP53 Y220C mutation and KRAS wild-type.
Read →
YourChoice Therapeutics Board Member Presents Male Contraceptive Phase 1a Study at ACS Spring 2024
Pharma Pioneer
2 min read
YourChoice Therapeutics Board Member Presents Male Contraceptive Phase 1a Study at ACS Spring 2024
19 May 2024
Gunda Georg, co-creator of YCT-529, presented an update on the phase 1a clinical trial of the novel hormone-free male contraceptive pill at the American Chemical Society's Spring Meeting in New Orleans
Read →
FDA Approves DepYmed's Phase 1 Trial for Rett Syndrome Drug DPM-1003
Pharma Pioneer
2 min read
FDA Approves DepYmed's Phase 1 Trial for Rett Syndrome Drug DPM-1003
19 May 2024
DepYmed Inc. has announced that it has obtained approval from the U.S. Food and Drug Administration (FDA) to begin phase 1 clinical trials for DPM-1003.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.